The ceramide synthase 2 (CERS2) antibody is a crucial tool for studying the role of CERS2. a key enzyme in sphingolipid metabolism. CERS2. also known as longevity assurance gene 2 (LASS2), belongs to the ceramide synthase family (CERS1-6), which catalyzes the synthesis of ceramides—central lipid molecules in sphingolipid biosynthesis. Specifically, CERS2 preferentially generates very-long-chain (C20–C26) ceramides, distinguishing it from other isoforms with shorter acyl-chain preferences. These ceramides are vital for maintaining membrane integrity, cellular signaling, and apoptosis regulation. Dysregulation of CERS2 has been implicated in pathologies including cancer, neurodegenerative disorders, and metabolic syndromes. For instance, reduced CERS2 expression correlates with tumor progression and chemoresistance, while mutations are linked to inherited neuropathies.
The CERS2 antibody enables researchers to detect and quantify CERS2 protein levels in tissues or cells via techniques like Western blotting, immunohistochemistry, or immunofluorescence. Its specificity helps delineate CERS2’s spatial expression and functional interplay in disease models. Recent studies also highlight its role in ER stress, autophagy, and lipid raft dynamics, underscoring its therapeutic potential. Available as monoclonal or polyclonal versions (commonly from rabbit or mouse hosts), the antibody’s validation in knockout controls ensures reliability. By elucidating CERS2’s mechanisms, this tool advances understanding of sphingolipid-related diseases and informs targeted therapeutic strategies.